DURHAM, N.C., June 28, 2011 /PRNewswire/ -- Argos Therapeutics today announced that Charles Nicolette, Ph.D., the company's chief scientific officer and vice president of research and development, will participate in a panel discussion titled "Looking to the Future: Innovative Approaches to HIV Vaccine Development and Immunotherapies" at 10 a.m. EDT, Wednesday, June 29, at the 2011 BIO International Convention in Washington D.C.
"This panel will provide valuable insight on the recent advancements in the fast-evolving field of HIV/AIDS vaccines and immunotherapies," said Dr. Nicolette. "Argos' RNA-loaded, dendritic cell-based immunotherapy for the treatment of HIV patients, AGS-004, utilizes small plasma samples from HIV patients to amplify large quantities of viral RNA encoding selected antigens, resulting in a personalized treatment to patients' own strain of virus. We have demonstrated that patients receiving AGS-004 have significantly lower viral loads after interrupting traditional drug therapy prior to initiating the ongoing Phase 2b clinical trial to further demonstrate its efficacy and safety for the treatment of HIV patients."
About the Arcelis Technology
Arcelis is Argos' proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies for cancer, HIV and other infectious diseases. This platform is based on optimizing a patient's own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response. To address the challenge of the unique genetic profile of each patient's disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA ("mRNA") isolated from the patient's disease. Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is customized to the patient's specific disease.
About Argos Therapeutics, Inc.
Argos is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases and transplantation rejection. The Company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells the master switch that turns the immune system on or off. www.argostherapeutics.com
David Schull or Andreas Marathovouniotis
Russo Partners LLC
(212) 845-4271 or (212) 845-4235
email@example.com or firstname.lastname@example.org
SOURCE Argos Therapeutics